Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.96 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.96 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 9/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235433 | 1.00 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL2764243 | 1.00 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL3909615 | 1.00 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL198082 | 1.00 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL29903954 | 1.00 | KEAP1 (0.96) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL6004238 | 0.98 | KEAP1 (0.93) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL8197629 | 0.98 | KEAP1 (0.93) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL8204903 | 0.98 | KEAP1 (0.93) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| Water SCHEMBL8898031 | 0.98 | KEAP1 (0.93) | KEAP1NFE2L2CHRM3CHRM2CHRM1 | |
| SCHEMBL415801 | 0.98 | KEAP1 (1.00) | KEAP1NFE2L2CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130316409-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2013-11-28 | — | — | US | claimed |
| EP-1242589-B1 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE ALPHA-SUBSTITUTED CARBOXYLIC ACIDS | VERENIUM CORP (US) | 2013-11-13 | — | — | EP | claimed |
| US-8501451-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2013-08-06 | — | — | US | claimed |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | claimed |
| US-20120009633-A1 | NITRILASES AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | claimed |
| US-8088613-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | VERENIUM CORPORATION (US) | 2012-01-03 | — | — | US | claimed |
| US-8034595-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2011-10-11 | — | — | US | claimed |
| EP-1880718-B1 | Pharmaceutical preparation for oral administration with controlled drug release in the small intestine colon and process of prepartion thereof | PFLEGER R CHEM FAB (DE) | 2011-09-21 | — | — | EP | claimed |
| US-20090285891-A1 | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | DR. R. PFLEGER CHEMISCHE FABRIK GMBH (DE) | 2009-11-19 | — | — | US | claimed |
| US-20090162906-A1 | Biocatalysts; mutant and/or chemically modified enzymes; stereoselectively hydrolyze an amino nitrile or cyanohydrin intermediate to produce the corresponding carboxylic acid; e.g. phenylglycinonitrile from benzaldehyde, potassium cyanide and ammonium chloride | VERENIUM CORPORATION (US) | 2009-06-25 | — | — | US | claimed |
| US-7300775-B2 | Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents | VERENIUM CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| US-6825378-B2 | TREATING CYCLOHEXYLPHENYL KETONE WITH YLIDE IN ANHYDROUS SOLVENT TO OBTAIN A-CYCLOHEXYLSTYRENE; DIHYDROXYLATION, OXIDATION | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-11-30 | — | — | US | claimed |
| US-20040192962-A1 | Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-09-30 | — | — | US | claimed |
| EP-1242589-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE ALPHA-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2002-09-25 | — | — | EP | claimed |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | VERENIUM CORPORATION | 2002-01-31 | — | — | US | claimed |
| WO-2001048175-A2 | METHODS FOR PRODUCING ENANTIOMERICALLY PURE α-SUBSTITUTED CARBOXYLIC ACIDS | DIVERSA CORPORATION (US) | 2001-07-05 | — | — | WO | claimed |
| US-10857517-B2 | Porous chiral materials and uses thereof | NANKAI UNIVERSITY (CN) | 2020-12-08 | — | — | US | disclosed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-5036107-A | Treatment of neurogenic bladder disorders | MARION MERRELL DOW INC. (US) | 1991-07-30 | — | — | US | disclosed |
| EP-0383256-A2 | A novel substituted-acetamide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009633-A1 | NITRILASES AND METHODS FOR MAKING AND USING THEM | ASNS, DNPEP, ASPH | KEAP1 799/4885NFE2L2 2064/4885CHRM3 2205/4885 |
| US-20090162906-A1 | Biocatalysts; mutant and/or chemically modified enzymes; stereoselectively hydrolyze an amino nitrile or cyanohydrin intermediate to produce the corresponding carboxylic acid; e.g. phenylglycinonitrile from benzaldehyde, potassium cyanide and ammonium chloride | PAH, ASPH, CPN1 | KEAP1 602/4885NFE2L2 2284/4885CHRM3 3405/4885 |
| US-20020012974-A1 | Genetic engineered nucleic acid promoter | RNGTT, ASPH, ALKBH3 | KEAP1 1528/4885NFE2L2 1429/4885CHRM3 4455/4885 |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | RNGTT, NSUN2, NSUN3 | KEAP1 2794/4885NFE2L2 2241/4885CHRM3 4489/4885 |
| US-10857517-B2 | Porous chiral materials and uses thereof | ANXA7, XDH, OPRM1 | KEAP1 3938/4885NFE2L2 4289/4885CHRM3 931/4885 |
| US-20040192962-A1 | Process for the synthesis of enantiomerically pure cyclohexylphenyl glycolic acid | GRHPR, PGD, HPD | KEAP1 1548/4885NFE2L2 2624/4885CHRM3 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.